BLLN · BillionToOne, Inc.
Price & Indicators
The closing range uses available history since Nov 6, 2025; less than a full year is stored.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. BillionToOne delivered 64% YoY revenue growth to $109.4M with 70.5% gross margin and GAAP operating income of $5.5M, while reiterating full-year 2026 revenue guidance of $450M–$465M. The company also highlighted new product launches (Unity Confirm, 130-gene Fetal Risk Screen, Northstar Origin), strong oncology momentum (176% YoY), and key catalysts ahead including MolDx coverage for Northstar Response and an MRD launch by year-end.
- + Q2 revenue grew 64% YoY to $109.4M, with test volume up 35% and ASP up 21%
- + Gross margin expanded to 70.5%, up 5 percentage points YoY
- + Achieved GAAP operating income of $5.5M (5% margin) and $5.1M free cash flow
- + Oncology revenue grew 176% YoY to $13.7M with volume ahead of expectations
- + Unity Confirm seeing strong adoption with over 50% opt-in among eligible high-risk patients
- + Northstar Response peer-reviewed study published supporting MolDx Medicare coverage pursuit
- − Operating margin declined from 16% in Q1 to 5% in Q2, driven in part by lower true-up
- − Held more than $10M of claims pending in-network implementation, creating temporary cash and true-up pressure
- − ASP declined ~$20 sequentially due to true-up timing differences
- − Overall COGS per test rose to $161 from $152 in Q1 due to oncology mix shift
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BLLN
this stock
BillionToOne, Inc.
|
$5.58B | +30.1% | +100.0% | — | 5.6% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +16.5% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$155.42B | -3.2% | +8.5% | 39.2 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +80.4% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +26.6% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BLLN | -7.0% | +15.3% | +29.0% | +17.4% | +30.1% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -6.3% | +15.2% | +16.9% | +18.0% | +18.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.